Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-13 of 13 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

Intranasal Trans-Sialidase Vaccine Mitigates Acute and Chronic Pathology in a Preclinical Oral Chagas Disease Model.
Pacini MF, Bulfoni Balbi C, Dinatale B, Farré C, Cacik P, Gonzalez FB, Marcipar I, Pérez AR
Vaccines (Basel), 12(10):1171, 15 Oct 2024
Cited by: 0 articles | PMID: 39460337 | PMCID: PMC11511307
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Intranasal Trans-Sialidase Vaccine Mitigates Acute and Chronic Pathology in a Preclinical Oral Chagas Disease Model
Pacini MF, Bulfoni Balbi C, Dinatale B, Farre C, Cacik P, Gonzalez FB, Marcipar I, Pérez AR
Preprints.org, 17 Sep 2024
Cited by: 0 articles | PPR: PPR910997
Add to export list Preprint v1
Systemic inflammatory Th1 cytokines during Trypanosoma cruzi infection disrupt the typical anatomical cell distribution and phenotypic/functional characteristics of various cell subsets within the thymus.
Viano ME, Baez NS, Savid-Frontera C, Baigorri RE, Dinatale B, Pacini MF, Bulfoni Balbi C, Gonzalez FB, Fozzatti L, Lidón NL, Young HA, Hodge DL, Cerban F, Stempin CC, Pérez AR, Rodriguez-Galán MC
Microbes Infect, 26(5-6):105337, 13 Apr 2024
Cited by: 0 articles | PMID: 38615883
Add to export list
The high identity of the Trypanosoma cruzi Group-I of trans-sialidases points them as promising vaccine immunogens.
Pacini MF, Perdomini A, Bulfoni Balbi C, Dinatale B, Herrera FE, Perez AR, Marcipar I
Proteins, 91(10):1444-1460, 16 Jun 2023
Cited by: 1 article | PMID: 37323089
Add to export list
Intranasal trans-sialidase-based vaccine against Trypanosoma cruzi triggers a mixed cytokine profile in the nasopharynx-associated lymphoid tissue and confers local and systemic immunogenicity.
Pacini MF, Balbi CB, Dinatale B, González FB, Prochetto E, De Hernández MA, Cribb P, Farré C, Espariz M, Blancato VS, Magni C, Marcipar I, Pérez AR
Acta Trop, 241:106889, 07 Mar 2023
Cited by: 2 articles | PMID: 36893830
Add to export list
Immunization With Lipopolysaccharide-Activated Dendritic Cells Generates a Specific CD8⁺ T Cell Response That Confers Partial Protection Against Infection With Trypanosoma cruzi.
Biscari L, Kaufman CD, Farré C, Huhn V, Pacini MF, Balbi CB, Gómez KA, Pérez AR, Alloatti A
Front Cell Infect Microbiol, 12:897133, 07 Jul 2022
Cited by: 6 articles | PMID: 35903201 | PMCID: PMC9318436
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Nasal immunization with a L. lactis-derived trans-sialidase antigen plus c-di-AMP protects against acute oral T. cruzi infection.
Pacini MF, González FB, Dinatale B, Bulfoni Balbi C, Villar SR, Farré C, Lupi G, Espariz M, Blancato VS, Magni C, Marcipar I, Pérez AR
Vaccine, 40(15):2311-2323, 09 Mar 2022
Cited by: 7 articles | PMID: 35279330
Add to export list
Assessment of a combined treatment with a therapeutic vaccine and benznidazole for the Trypanosoma cruzi chronic infection.
Prochetto E, Bontempi I, Rodeles L, Cabrera G, Vicco M, Cacik P, Pacini MF, Pérez Gianeselli M, Pérez AR, Marcipar I
Acta Trop, 229:106334, 29 Jan 2022
Cited by: 6 articles | PMID: 35101415
Add to export list
Chagas disease reactivation in rheumatologic patients: association with immunosuppressive therapy and humoral response.
Ringer A, Ruffino JP, Leiva R, Cuadranti N, Argento MC, Martínez MF, Rolla I, Chulibert S, Carbone D, Palatnik M, Cortese MN, Lagrutta M, Córdoba L, González FB, Pacini MF, Villar SR, Águila D, Bottasso OA, Pérez AR, Abdala M
Clin Rheumatol, 40(7):2955-2963, 12 Jan 2021
Cited by: 5 articles | PMID: 33438080
Add to export list
Activation of PPARγ reduces N-acetyl-cysteine -induced hypercorticoidism by down-regulating MC2R expression into adrenal glands.
Ventura RD, Chaves AS, Magalhães NS, Gonzalez FB, Pacini MF, Pérez AR, Silva PMR, Martins MA, Carvalho VF
Free Radic Biol Med, 156:137-143, 20 Jun 2020
Cited by: 4 articles | PMID: 32574682
Add to export list
Immune-neuroendocrine and metabolic disorders in human and experimental T. cruzi infection: New clues for understanding Chagas disease pathology.
González FB, Villar SR, Pacini MF, Bottasso OA, Pérez AR
Biochim Biophys Acta Mol Basis Dis, 1866(3):165642, 19 Dec 2019
Cited by: 7 articles | PMID: 31866417
Add to export list Review
Immune response triggered by Trypanosoma cruzi infection strikes adipose tissue homeostasis altering lipid storage, enzyme profile and adipokine expression.
González FB, Villar SR, Toneatto J, Pacini MF, Márquez J, D'Attilio L, Bottasso OA, Piwien-Pilipuk G, Pérez AR
Med Microbiol Immunol, 208(5):651-666, 09 Nov 2018
Cited by: 15 articles | PMID: 30413884
Add to export list
Genetic Engineering of Lactococcus lactis Co-producing Antigen and the Mucosal Adjuvant 3' 5'- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype.
Quintana I, Espariz M, Villar SR, González FB, Pacini MF, Cabrera G, Bontempi I, Prochetto E, Stülke J, Perez AR, Marcipar I, Blancato V, Magni C
Front Microbiol, 9:2100, 04 Sep 2018
Cited by: 12 articles | PMID: 30258417 | PMCID: PMC6143824
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-13 of 13 results

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Intranasal Trans-Sialidase Vaccine Mitigates Acute and Chronic Pathology in a Preclinical Oral Chagas Disease Model.

Intranasal Trans-Sialidase Vaccine Mitigates Acute and Chronic Pathology in a Preclinical Oral Chagas Disease Model

Systemic inflammatory Th1 cytokines during Trypanosoma cruzi infection disrupt the typical anatomical cell distribution and phenotypic/functional characteristics of various cell subsets within the thymus.

The high identity of the Trypanosoma cruzi Group-I of trans-sialidases points them as promising vaccine immunogens.

Intranasal trans-sialidase-based vaccine against Trypanosoma cruzi triggers a mixed cytokine profile in the nasopharynx-associated lymphoid tissue and confers local and systemic immunogenicity.

Immunization With Lipopolysaccharide-Activated Dendritic Cells Generates a Specific CD8⁺ T Cell Response That Confers Partial Protection Against Infection With Trypanosoma cruzi.

Nasal immunization with a L. lactis-derived trans-sialidase antigen plus c-di-AMP protects against acute oral T. cruzi infection.

Assessment of a combined treatment with a therapeutic vaccine and benznidazole for the Trypanosoma cruzi chronic infection.

Chagas disease reactivation in rheumatologic patients: association with immunosuppressive therapy and humoral response.

Activation of PPARγ reduces N-acetyl-cysteine -induced hypercorticoidism by down-regulating MC2R expression into adrenal glands.

Immune-neuroendocrine and metabolic disorders in human and experimental T. cruzi infection: New clues for understanding Chagas disease pathology.

Immune response triggered by Trypanosoma cruzi infection strikes adipose tissue homeostasis altering lipid storage, enzyme profile and adipokine expression.

Genetic Engineering of Lactococcus lactis Co-producing Antigen and the Mucosal Adjuvant 3' 5'- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype.

Partnerships & funding